SLC5A2 and hydrops fetalis: As ongoing trials validate the efficacy of SGLT-2 inhibitors for HF prevention in other subgroups, such as those with chronic kidney disease, future guidelines may be able to broaden the patient populations in which SGLT-2 inhibitors are recommended; SGLT-2 inhibitors could potentially take a place in heart failure prevention akin to statins for atherosclerotic cardiovascular disease prevention (44).